The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-13 and is reviewed periodically as new material appears.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
== Co-culture composition and conditions == Based on the desired product of the SCOBY, different species of bacteria and yeast are used. Such cultures generally include aerobic, gram negative AAB species such as Acetobacter, Gluconobacter and Komagataeibacter, aerobic, gram positive LAB such as Lactobacillus, as well as various yeasts such as Saccharomyces and Zygosaccharomyces. Strains are pre-screened for viability under compatible conditions, increased yield of desired product, and indisposition to compete; once chosen, various culture conditions are modified for optimal growth and productivity. For kombucha SCOBYs, the first step is yeast fermentation of sugars such as glucose from black or green tea into ethanol and carbon dioxide. Zygosaccharomyces is reported to be involved in 84.1% of all kombucha SCOBY fermentation processes due to its improved stability in high sugar and halophilic conditions, while Saccharomyces is predominantly used for its efficient fermentation rates and resistance to high temperature and alcohol content. Different variations of yeast can also be added as either a supplemental means to introduce different flavors and aromas or ensure reaction completion by utilizing different niches. While these niches vary yeast to yeast, certain fermentation conditions remain consistent. Such conditions include but are not limited to high substrate concentration, sufficient oxygen levels, temperatures of 20–30 °C (68–86 °F), and a pH between 4–4.5.
The following is a partial list of the "D" codes for Medical Subject Headings (MeSH), as defined by the United States National Library of Medicine (NLM). This list continues the information at List of MeSH codes (D06). Codes following these are found at List of MeSH codes (D09). For other MeSH codes, see List of MeSH codes. The source for this content is the set of 2006 MeSH Trees from the NLM.
=== 1974 === 16 April: Thérèse Siegenthaler (21). A sociology student at Greenwich Community College, Siegenthaler was abducted by the Wests as she hitchhiked from South London to Holyhead. Fred mistook her Swiss accent for Dutch and always referred to her as either "the Dutch girl" or "Tulip". She was reported missing to Scotland Yard by her family in Switzerland when communication from their daughter abruptly ceased. Fred later further concealed Siegenthaler's remains by building a false chimney breast on her grave. 15 November: Shirley Hubbard (15). A foster child abducted from a Droitwich bus stop close to the River Severn as she travelled home from a date. Aged 15 when murdered, Hubbard had been attending work experience in Worcester and was last seen by her boyfriend, having promised to meet him the next day. Her dismembered remains were found in a section of the cellar known to the family as the "Marilyn Monroe area". Hubbard's head had been completely covered in tape, with a one-eighth-inch (3.2 mm) diameter rubber tube inserted three inches (7.6 cm) into her nasal cavity to enable her to breathe.
=== Retinol esters have been used as markers === Retinyl esters can be distinguished from retinol in serum and other tissues and quantified with the use of methods such as high-performance liquid chromatography. Elevated amounts of retinyl ester (i.e., >10% of total circulating vitamin A) in the fasting state have been used as markers for chronic hypervitaminosis A in humans and monkeys. This increased retinyl ester may be due to decreased hepatic uptake of vitamin A and the leaking of esters into the bloodstream from saturated hepatic stellate cells.
King Crimson were an English progressive rock band formed in London in 1968. Pioneered by guitarist and primary composer Robert Fripp—the group's sole constant member throughout their history—the band are widely regarded as a foundational catalyst of the progressive rock movement. They drew inspiration from an expansive array of musical styles, incorporating elements of classical, jazz, folk, heavy metal, gamelan, post-punk, industrial, and experimental music. Beyond shaping contemporaries such as Yes and Genesis, King Crimson's genre-spanning innovations have exerted a lasting influence on subsequent generations of alternative rock, metal, and math rock artists, earning the band a enduring global cult following. The band was initially formed by Fripp alongside Michael Giles, Greg Lake, Ian McDonald, and lyricist Peter Sinfield. Their debut album, In the Court of the Crimson King (1969), achieved immediate critical and commercial success, and is widely cited by music historians as a definitive cornerstone of progressive rock. Following the rapid dissolution of the original line-up, the group endured a period of personnel instability, releasing In the Wake of Poseidon (1970), Lizard (1970), and Islands (1971). In 1972, Fripp refashioned the band's direction by recruiting Bill Bruford, John Wetton, David Cross, and Jamie Muir, alongside lyricist Richard Palmer-James.
Sources: en.wikipedia.org
1993/3066) International Carriage of Dangerous Goods by Road (Fees) (Amendment) Regulations 1993 (S.I. 1993/3067) International Transport of Goods under Cover of TIR Carnets (Fees) (Amendment) Regulations 1993 (S.I. 1993/3068) Children (Homes, Arrangements for Placement, Reviews and Representations) (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/3069) Education (Publication of Schemes for Financing Schools) Regulations 1993 (S.I. 1993/3070) Common Agricultural Policy (Wine) (Amendment) Regulations 1993 (S.I. 1993/3071) Education (Acquisition of Grant–maintained Status) (Transitional Functions) Regulations 1993 (S.I. 1993/3072) Education (Grant–maintained Schools) (Loans) Regulations 1993 (S.I. 1993/3073) Personal Protective Equipment (EC Directive) (Amendment) Regulations 1993 (S.I. 1993/3074) Prison (Amendment) (No. 2) Rules 1993 (S.I. 1993/3075) Young Offender Institution (Amendment) Rules 1993 (S.I. 1993/3076) Non–Domestic Rating Contributions (Wales) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/3077) A1 Trunk Road (Holloway Road, Islington) (Prescribed Routes) Order 1993 (S.I. 1993/3078) Fire Services (Appointments and Promotion) (Scotland) Amendment Regulations 1993 (S.I. 1993/3079) Act of Sederunt (Fees of Solicitors in the Sheriff Court) (Amendment and Further Provisions) 1993 (S.I. 1993/3080) Police (Scotland) Amendment Regulations 1993 (S.I. 1993/3081) Non-Domestic Rating Contributions (England) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/3082) Boiler (Efficiency) Regulations 1993 (S.I.
=== Ethanol === The first historical achievement in anesthesia occurred around 4000 BC in ancient Mesopotamia. This was the advent of ethanol (commonly known as drinking alcohol), the first general anaesthetic agent. These accounts of the anesthetic uses of ethanol come from the oldest known historical civilization of Sumer and are documented in the oldest known writing system cuneiform.
Chris Webb wins the 2024 Blackpool South by-election, with a 26% swing to Labour. Research carried out by the University of Leicester suggests squirrels may have passed leprosy on to mediaeval humans in the UK. 4 May 2024 London mayoral election: Labour's Sadiq Khan secures a third term as Mayor of London with 44% of the vote, beating the Conservative Susan Hall on 33%. 2024 West Midlands mayoral election: Labour's Richard Parker narrowly defeats the Conservative incumbent Andy Street to become Mayor of the West Midlands. 2024 Greater Manchester mayoral election: Labour's Andy Burnham secures a third term as Mayor of Greater Manchester with almost two-thirds of the votes cast. 5 May – With all votes counted, the results from the local elections in England are: Labour 1,158 (+186), Liberal Democrat 522 (+104), Conservative 515 (−474), Independents and others 228 (+93), Green 181 (+74), Residents' Association 48 (+11), Workers Party of Britain 4 (+4), Reform UK 2 (+2). 6 May King Charles III, celebrates the first anniversary of his coronation. The NHS will roll out laser interstitial thermal therapy (known as LITT) next month in England to help reduce seizures for patients with epilepsy that cannot be controlled by standard anti-seizure drugs. John Swinney is confirmed as Leader of the Scottish National Party after being unopposed in the leadership election, and begins his second tenure in the post. Heineken announces plans to reopen UK pubs that were previously closed and to invest £39m in refurbishments.
=== Lungs === Individuals with Marfan syndrome may be affected by various lung-related problems. Spontaneous pneumothorax can be present, but is not common. In spontaneous unilateral pneumothorax, air escapes from a lung and occupies the pleural space between the chest wall and a lung. The lung becomes partially compressed or collapsed. This can cause pain, shortness of breath, cyanosis, and if not treated, death. Other possible pulmonary manifestations of MFS include sleep apnea, which is typically treated with BiPAP. and idiopathic obstructive lung disease. Pathologic changes in the lungs have been described such as cystic changes, emphysema, pneumonia, bronchiectasis, bullae, apical fibrosis and congenital malformations such as middle lobe hypoplasia.
=== Gene === The human LECT2 gene, LECT2, is located on the long, i.e., "q", arm of chromosome 5 at position q31.1 (notated as 5q31.1). This location is close to several immune modulating genes including interleukins 3, 5, and 9 and granulocyte-macrophage colony stimulating factor. LECT2 is conserved in zebrafish, chicken, rat, mouse, cow. dog, Rhesus monkey, and chimpanzee. Human LECT2 is composed of 4 exons, 3 introns, and ~8,000 base pairs. The gene has numerous single nucleotide variants as well as other variations, two of which (see Pathophysiology section) have been associated with human disease. Human LECT2 has several different transcriptional initiation sights and codes for a mRNA composed of 1,000 to 1,300 ribonucleotides. mRNA for LECT2 is highly expressed in liver tissue and expressed at far lower levels in a wide range of other tssues.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.